Contact Us
Drug Search Results
More Filters [+]

SAR407899

Alternative Names: sar407899
Latest Update: 2019-02-07
Latest Update Note: News Article

Product Description

Mechanisms of Action: ROCK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SAR407899

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Coronary Artery Disease|Microvascular Angina|Angina, Stable|Myocardial Ischemia|Erectile Dysfunction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ACT14656

P2

Terminated

Coronary Artery Disease|Myocardial Ischemia|Microvascular Angina|Angina, Stable

2018-07-23

2016-000629-38

P2

Completed

Coronary Artery Disease

2018-07-23

RHOKET

P2

Completed

Erectile Dysfunction

2009-09-01

Recent News Events

Date

Type

Title

02/07/2019

News Article

 Sanofi delivers 2018 business EPS growth of 5.1% at CER

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions